Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

Los Expertos Eligen los Avances Más Importantes de 2011

Jason Kahn

March 08, 2012

News Daily News

Estudio se Centra en la Inflamación Sistémica tras la TAVR

Caitlin E. Cox

March 07, 2012

News Daily News

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

L.A. McKeown

March 06, 2012

Presentation TCT 2012

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Presenter: Paul S. Rees, Sean M. Davidson, Sian E. Harding, Perry M. Elliott, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Advertisement

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Los Expertos Eligen los Avances Más Importantes de 2011

Estudio se Centra en la Inflamación Sistémica tras la TAVR

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content